Fluorescent reverse transcription-PCR assay for determination of hepatitis C virus genotypes

Guo XinHui; Yan Yan; Li Zhuo; Yin JiMing

Issue 1

Jan. 2011

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2011 > 27(1): 65-67

PDF( 2519 KB)

Fluorescent reverse transcription-PCR assay for determination of hepatitis C virus genotypes

Published Date: 2011-01-20

Abstract

Abstract

Objective To analyze the genotype of blood borne hepatitis C virus (HCV) using fluorescent reverse transcription-PCR (RT-PCR) method.Methods Fluorescent reverse transcription polymerase chain reaction (RT-PCR) detection of HCV RNA was used for the genotype determination of 118 serum samples from HCV patients and compared with sequncing assay of 98 clinical samples from HBV patients checked as negative control.Results Fluorescent RT-PCR result from 118 samples of HCV patients showed 79 (66.9%) were genotype 1, 29 (24.6%) were genotype 2, 8 (6.8%) were genotype 1 and genotype 2 mixed, While 2 (1.7%) samples were non-reactive because HCV RNA was less than 1×103IU/ml.Sequence assay showed, 81 (68.4%) were genotype 1, 29 (24.6%) were genotype 2, 6 (5.1%) were genotype 1 and genotype 2 mixed, 2 (1.7%) were non-reactive also.In control group the samples from HBV patients were negative for HCV genotype detection.Conclusion The fluorescent RT-PCR was sensitive, specific, repeatable and convenient for HCV genotyping and could be used for clinical genotyping.
- hepatitis C,
- genotype,
- reverse transcriptase polymerase chain reaction

FullText(HTML)

References(10)

References

[1]中华医学会.丙型肝炎防治指南[J].中华肝脏病杂志, 2004, 12 (4) :194-198.

[2]Simmonds P, Holmes EC, Cha TA, et al.Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region[J].J Gen Virol, 1993, 74 (11) :2391-2399.

[3]Moreno C, Deltenre P, Pawlotsky JM, et al.Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response:a meta-analysis[J].J Hepatol, 2010, 52 (1) :25-31.

[4]Mangia A, Santoro R, Andriulli A, et al.Peginterferon alfa-2b and ribavirin for 12 vs.24 weeks in HCV genotype 2 or 3[J].N Engl J Med, 2005, 352 (25) :2609-2617.

[5]Davis GL, Wong JB, McHutchison JG, et al.Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C[J].Hepatology, 2003, 38 (3) :645-652.

[6]Wong JB, Davis GL, McHutchinson JG, et al.Clinical implications of testing viral response during ribavirin and peginterferon alfa-2b treatment for chronic hepatitis C[J].Hepatology, 2002, 36:281A.

[7]Bullock C, Bruns E, Haverstick DM, et al.Hepatitis C genotype determination by melting curve analysis with a single set of fluorescent resonance energy transfer probes[J].Clin Chem, 2002, 48 (12) :2147-2154.

[8]Fujigaki H, Takemura M, Takahashi K, et al.Genotyping of hepatitis C virus by melting curve analysis with SYBR green I[J].Ann Clin Biochem, 2004, 41 (Pt2) :130-132.

[9]Linda C, Ka WS, Elizabeth M, et al.Mul-tiplex Real-Time Reverse Transcription-PCR Assay for Determination of Hepatitis C Virus Genotypes[J].J Clin Microbiol, 2006, 41 (11) :1091-1100.

[10]Rolfe KJ, Alexander GJ, Wreghitt TG, et al.A real-time Taqman method for hepatitis C virus genotyping[J].J Clin Virol, 2005, 34 (2) :115-121.

Relative Articles

[1]	Shiyu YUAN, Huanhuan YANG, Yingmei TANG. Role of T-cell immunoglobulin and mucin domain-containing molecule 3 in the development and progression of liver diseases[J]. Journal of Clinical Hepatology, 2024, 40(6): 1275-1280. doi: 10.12449/JCH240632
[2]	Sisi WANG, Yaru WANG, Rui LIU, Jie QIN. Mechanism of action and potential therapeutic targets of ferroptosis suppressor protein 1 in liver diseases[J]. Journal of Clinical Hepatology, 2024, 40(7): 1493-1497. doi: 10.12449/JCH240731
[3]	Chenlu HAN, Haijun LIANG, Daokun YANG, Haiyan CHANG, Shuai WEI, Xingwei WANG, Haili GAO. Expression levels of serum high-mobility group box 1， soluble CD163， and prostaglandin E2 in patients with hepatitis B virus-related chronic-on-acute liver failure and their value in predicting prognosis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1130-1135. doi: 10.12449/JCH240610
[4]	Yan YANG, Feilin GE, Qian HUANG, Xinyue ZHANG, Rui ZENG, Xiaohe XIAO, Zhaofang BAI, Qin SUN. Mechanism of action of nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome in liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(4): 942-946. doi: 10.3969/j.issn.1001-5256.2022.04.041
[5]	Laying ZHANG, Mingkai CHEN. Research advances in the mechanism of action of TRPV4 ion channel protein in liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(1): 224-227. doi: 10.3969/j.issn.1001-5256.2022.01.040
[6]	Zhengguang LIAO, Shihui WEI, Danyu DU, Li SUN, Shengtao YUAN. Role of lipocalin-2 in the development and progression of liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(9): 2177-2181. doi: 10.3969/j.issn.1001-5256.2022.09.044
[7]	Xia WU, Xiaoning ZHU, Yurong ZHANG, Yue YIN, Mengyun PENG, Ding ZHENG, Jing WANG. Mechanism of action of suppressor of cytokine signaling 1 in the development and progression of liver inflammatory diseases[J]. Journal of Clinical Hepatology, 2021, 37(4): 973-976. doi: 10.3969/j.issn.1001-5256.2021.04.055
[8]	Yang ShangQing, Yang DongLiang, Liu Jia. Role of matrix metalloproteinases-2 and matrix metalloproteinases-9 in the development and progression of chronic liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(10): 2364-2369. doi: 10.3969/j.issn.1001-5256.2020.10.045
[9]	Wang ShanShan, Zhang QingShan, Zhao SuXian, Kong LingBo, Ji Lei, Kong Li. The immunoregulatory effect of tumor necrosis factor-alpha-induced protein 8-like 2 in different liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(2): 460-463. doi: 10.3969/j.issn.1001-5256.2020.02.050
[10]	Ye QianLing, Mao DeWen, Wang MingGang, Wang Na. Role of NLRP3 inflammasome in the development and progression of liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(10): 2346-2350. doi: 10.3969/j.issn.1001-5256.2019.10.048
[11]	Pan SiYu, Wang ZhiXin, ZHOU Ying, Wang Tao, Yin Jie, Wang Qiang, Fan HaiNing. Function and mechanism of action of the PD-1/PD-L1 pathway in liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(3): 672-676. doi: 10.3969/j.issn.1001-5256.2019.03.050
[12]	Pu MinJing, Zhao HongXian, Bo Chao, Zhou XiangYu, Chen Xia. Role and mechanism of the high-mobility group box 1/Toll-like receptor 9 signaling pathway in intestinal mucosal barrier injury in severe acute pancreatitis[J]. Journal of Clinical Hepatology, 2019, 35(5): 1037-1040. doi: 10.3969/j.issn.1001-5256.2019.05.020
[13]	Yang XinYing, Kang FuBiao, Ye LiHong, Dai ErHei, Sun DianXing. Level of high-mobility group box 1 in patients with chronic hepatitis B and liver cirrhosis and its clinical significance[J]. Journal of Clinical Hepatology, 2018, 34(9): 1901-1904. doi: 10.3969/j.issn.1001-5256.2018.09.015
[14]	Wei FengXian, Liu Zhao, Geng Jie, Su GuoHong, Chen Mo, Wang ManCai, Cao WeiJia, Zhang YouCheng. Research advances in association between Golgi protein 73 and liver diseases[J]. Journal of Clinical Hepatology, 2017, 33(8): 1595-1598. doi: 10.3969/j.issn.1001-5256.2017.08.040
[15]	Li Chen, Chen Jing, Liu HongLing, Zhu Bing, Zang Hong, You ShaoLi, Xin ShaoJie. One case of primary hepatic amyloidosis[J]. Journal of Clinical Hepatology, 2013, 29(10): 790-792. doi: 10.3969/j.issn.1001-5256.2013.10.017
[16]	Zhang Qian, Han Tao. Research progress in advanced oxidation protein products in liver diseases[J]. Journal of Clinical Hepatology, 2013, 29(8): 581-584. doi: 10.3969/j.issn.1001-5256.2013.08.007
[17]	Xu Fang, Liu Jun, Gao PuJun. Severe liver injury with hyperthyroidism : a case report[J]. Journal of Clinical Hepatology, 2011, 27(10): 1096-1098.
[18]	Niu ChunYan, Zheng JianYun, Li Lei, Gao BaoHua, Liu Bing, Luo JianMei. The expression and significance of HMGB1 in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(8): 807-809.
[19]	Gao BaoHua, Wang Wen, Niu ChunYan, Zheng JianYun, Liu Bing, Luo JianMei. The expression of HMGB1 in hepatocellular carcinoma, paracancerous liver tissue and its significance[J]. Journal of Clinical Hepatology, 2011, 27(8): 850-853.

Supplements(0)

Cited By

Cited by

Periodical cited type(19)

1.	高毅，舒劲，卢雨蓓，刘顺庆，马国珍. 门脉高压性胃病患者中医证型分布特点及其与胃镜下黏膜病变的相关性. 西部中医药. 2024(05): 76-78 .
2.	黄德峰. 内镜下组织粘合剂注射与硬化剂注射治疗肝硬化食管胃底静脉曲张的疗效比较. 临床医学. 2024(06): 29-31 .
3.	孙莉. 基于PDCA循环的护理模式对肝硬化患者医护依从性及生存质量的影响分析. 青海医药杂志. 2024(07): 23-26 .
4.	王薇，晁霞，周道颖，韩曼. 超声内镜检查术对食管-胃底静脉曲张患者食管静脉曲张套扎术治疗效果的评价. 中国内镜杂志. 2023(05): 52-56 .
5.	刘倩怡，刘智尚，李杰峰，黎嘉妍. 内镜下套扎和组织胶注射治疗食管和胃底静脉曲张的效果分析. 中国实用医药. 2023(12): 13-16 .
6.	史日东，赵翠娟. 内镜下精准食管胃静脉曲张断流术和传统内镜下套扎对食管胃静脉曲张疗效及早期再出血的预防. 现代消化及介入诊疗. 2023(04): 447-450 .
7.	柳舟，张亮，王璐，喻淑慧，曹明为，柯全，董卫国. 内镜下套扎术与硬化剂注射术治疗食管胃底静脉曲张出血的Meta分析. 微循环学杂志. 2023(03): 46-58 .
8.	方蕾，朱元东，章復龙，周丹. 钛夹联合注射治疗门高压症食管胃底静脉曲张出血94例报告. 浙江创伤外科. 2023(07): 1322-1324 .
9.	王钧，王耿泽. 胃镜下硬化术联合组织胶注射术治疗食管胃底静脉曲张破裂出血的临床研究. 实用中西医结合临床. 2023(19): 46-49 .
10.	张攀. 内镜下套扎术联合硬化剂注射对食管静脉曲张破裂出血患者的疗效观察. 医疗装备. 2023(21): 13-16 .
11.	莫志旺，黄福林，王囡囡，朱国锋. 急性静脉曲张性上消化道出血患者行胃镜下注射组织胶联合生长抑素治疗的效果与并发症分析. 基层医学论坛. 2022(19): 50-52 .
12.	王亚军，陈莹. 内镜下套扎术治疗肝硬化合并上消化道出血的临床效果及安全性. 临床医学研究与实践. 2022(31): 86-89 .
13.	王青. 金属夹联合组织胶注射治疗胃静脉曲张伴自发性门体分流的效果分析. 中国实用乡村医生杂志. 2022(09): 44-47 .
14.	刘昆毅，史程怡，王娜. 影响急诊内镜治疗效果相关因素的研究进展. 河北医科大学学报. 2022(11): 1361-1365 .
15.	常东方，梅浙川，何松，郭进军，邓磊. 内镜下套扎术与组织胶注射术治疗1型胃食管静脉曲张破裂出血的疗效观察. 重庆医科大学学报. 2021(02): 252-256 .
16.	李莉，丁鹏鹏，陈建宏，王亚丹，郭春梅，孟明明，王艳玲，祁小宝，张文辉，刘红. 急诊内镜治疗慢加急性肝衰竭合并食管胃静脉曲张破裂出血效果的影响因素. 临床肝胆病杂志. 2021(05): 1142-1146 . 本站查看
17.	张静文. 内镜下密集套扎联合胃底曲张静脉组织胶注射治疗食管胃底静脉曲张患者的疗效评价. 黑龙江医学. 2021(11): 1174-1175 .
18.	吴妹，王云芳，刘珍. 急诊胃镜下不同止血方式治疗食管胃交界区静脉曲张破裂出血患者的效果及安全性. 医疗装备. 2021(18): 88-89 .
19.	高毅，舒劲，卢雨蓓，刘顺庆，马国珍. 门脉高压性胃病不同中医证型分布与胃镜下黏膜病变特点分析. 甘肃医药. 2020(10): 908-910 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2834) PDF downloads(1263)

Fluorescent reverse transcription-PCR assay for determination of hepatitis C virus genotypes